Global Finance News
14 Aug 2026, 16:03
Zoetis Secures FDA Emergency Authorization for Simparica Trio Against New World Screwworm
Zoetis (NYSE: ZTS) has received Emergency Use Authorization from the U.S. Food and Drug Administration for Simparica Trio to treat New World screwworm infestations in dogs and puppies, expanding the animal-health company’s response to the emerging parasite threat.
New World screwworm larvae feed on the living tissue of animals, including pets, livestock and wildlife, and untreated infestations can cause severe injury, pain and death. Zoetis said the threat has recently prompted several U.S. states to introduce treatment requirements for domestic animals moving across borders from affected areas.
Simparica Trio Gains Important New Emergency Use
Simparica Trio is already a major Zoetis parasite-control product, providing monthly protection against heartworm disease, fleas, ticks, roundworms and hookworms. The FDA authorization now permits its emergency use for treatment of New World screwworm larvae in dogs and puppies.
Importantly, the authorization is an EUA rather than a full FDA approval for the new indication. The emergency authorization remains effective only while the conditions supporting the FDA's emergency declaration remain in place, unless it is revoked earlier.
Zoetis Expands Multi-Species Screwworm Response
The authorization broadens Zoetis' response beyond livestock. The company already offers Dectomax-CA1 for New World screwworm prevention and treatment in cattle, while emergency authorizations also cover certain uses of Dectomax products in dairy cattle, swine, sheep, deer and horses.
For Zoetis, the Simparica Trio authorization strengthens its position in parasite control while demonstrating the company's ability to rapidly extend existing products in response to emerging animal-health threats. Although the immediate financial contribution is uncertain, the authorization could support Simparica Trio's strategic importance within Zoetis' companion-animal portfolio if the New World screwworm threat continues to expand in the U.S.
Zoetis (NYSE: ZTS) has received Emergency Use Authorization from the U.S. Food and Drug Administration for Simparica Trio to treat New World screwworm infestations in dogs and puppies, expanding the animal-health company’s response to the emerging parasite threat.
New World screwworm larvae feed on the living tissue of animals, including pets, livestock and wildlife, and untreated infestations can cause severe injury, pain and death. Zoetis said the threat has recently prompted several U.S. states to introduce treatment requirements for domestic animals moving across borders from affected areas.
Simparica Trio Gains Important New Emergency Use
Simparica Trio is already a major Zoetis parasite-control product, providing monthly protection against heartworm disease, fleas, ticks, roundworms and hookworms. The FDA authorization now permits its emergency use for treatment of New World screwworm larvae in dogs and puppies.
Importantly, the authorization is an EUA rather than a full FDA approval for the new indication. The emergency authorization remains effective only while the conditions supporting the FDA's emergency declaration remain in place, unless it is revoked earlier.
Zoetis Expands Multi-Species Screwworm Response
The authorization broadens Zoetis' response beyond livestock. The company already offers Dectomax-CA1 for New World screwworm prevention and treatment in cattle, while emergency authorizations also cover certain uses of Dectomax products in dairy cattle, swine, sheep, deer and horses.
For Zoetis, the Simparica Trio authorization strengthens its position in parasite control while demonstrating the company's ability to rapidly extend existing products in response to emerging animal-health threats. Although the immediate financial contribution is uncertain, the authorization could support Simparica Trio's strategic importance within Zoetis' companion-animal portfolio if the New World screwworm threat continues to expand in the U.S.